why choose us

First received: July 21, 2022

Clinical Trial: Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab

Study Status: Completed

Recruit Status: RECRUITING

Condition: Resectable Non-Small Cell Lung Cancer

Study Type: INTERVENTIONAL


Official Title: Phase 2 Trial of Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab in Resectable Non-Small Cell Lung Cancer (Neo-KAN)

Brief Summary: This is an open label phase 2 clinical trial evaluating the clinical safety, feasibility and efficacy of neoadjuvant Adagrasib alone or in combination with nivolumab in patients with NSCLC with KRAS G12C mutation.

Read more